Successful management of infusion reaction accompanying the start of cetuximab therapy
Language English Country Germany Media print-electronic
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Adenocarcinoma drug therapy secondary MeSH
- Cetuximab MeSH
- Dexamethasone therapeutic use MeSH
- Glucocorticoids therapeutic use MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Infusion Pumps adverse effects MeSH
- Drug Hypersensitivity drug therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Antibodies, Monoclonal administration & dosage adverse effects MeSH
- Liver Neoplasms drug therapy secondary MeSH
- Sigmoid Neoplasms drug therapy pathology MeSH
- Antineoplastic Agents administration & dosage adverse effects MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cetuximab MeSH
- Dexamethasone MeSH
- Glucocorticoids MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Antibodies, Monoclonal MeSH
- Antineoplastic Agents MeSH
INTRODUCTION: Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal carcinoma after failure of standard chemotherapy. Rare infusion reactions that resulted in the cessation of therapy have been described after cetuximab administration. CASE DESCRIPTION: We have observed severe infusion reactions accompanied by a loss of consciousness in two patients. The patients were transferred to intensive care unit, and the treatment was continued after administration of corticosteroids under careful monitoring of vital signs without any further serious reactions. In both cases, benefit of therapy with cetuximab could be demonstrated. CONCLUSION: This experience indicates that cetuximab can be continued in patients who experience infusion reactions. Surveillance in the intensive care unit is mandatory during readministration of the drug.
See more in PubMed
Inflamm Bowel Dis. 2001 Feb;7(1):34-7 PubMed
Am J Gastroenterol. 2003 Jun;98(6):1315-24 PubMed
Br J Haematol. 2001 Dec;115(4):807-11 PubMed
Cancer Metastasis Rev. 2005 Dec;24(4):487-99 PubMed
N Engl J Med. 2004 Jul 22;351(4):337-45 PubMed
J Clin Oncol. 1999 Mar;17(3):791-5 PubMed
Clin Cancer Res. 2001 May;7(5):1204-13 PubMed
J Clin Oncol. 2004 Apr 1;22(7):1201-8 PubMed
N Engl J Med. 2006 Feb 9;354(6):567-78 PubMed
Cancer Metastasis Rev. 1999;18(4):465-71 PubMed
